Career history of Eric Feldman
Former positions of Eric Feldman
| Companies | Position | Start | End |
|---|---|---|---|
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 2017-07-31 | 2019-03-31 |
| SEAGEN INC. | Chief Tech/Sci/R&D Officer | 2013-12-31 | 2017-11-30 |
NewYork-Presbyterian Hospital
 NewYork-Presbyterian Hospital Hospital/Nursing ManagementHealth Services NewYork-Presbyterian Hospital offers healthcare services. Its services include surgery, corporate health, nephrology, dermatology, cardiology, hepatology, vascular care, emergency care, and ambulatory care. The company was founded in 1771 and is headquartered in New York, NY. | Corporate Officer/Principal | - | - |
| GLYCOMIMETICS, INC. | Chief Tech/Sci/R&D Officer | 2021-03-18 | - |
| Corporate Officer/Principal | 2019-04-28 | 2021-03-18 |
Training of Eric Feldman
| Tulane University (Louisiana) | Undergraduate Degree |
| New York Medical College | Undergraduate Degree |
Statistics
International
| United States | 7 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 2 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Retail Trade | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
NewYork-Presbyterian Hospital
NewYork-Presbyterian Hospital Hospital/Nursing ManagementHealth Services NewYork-Presbyterian Hospital offers healthcare services. Its services include surgery, corporate health, nephrology, dermatology, cardiology, hepatology, vascular care, emergency care, and ambulatory care. The company was founded in 1771 and is headquartered in New York, NY. | Health Services |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Stock Market
- Insiders
- Eric Feldman
- Experience
